Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse and / or Refractory Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06615479
What this trial is testing

Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 440
Not applicableUnknownNCT03903406
What this trial is testing

Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Multinational Center for Quality of Life Research, Russia 40
Early research (Phase 1)Study completedNCT03111992
What this trial is testing

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Novartis Pharmaceuticals 26
Testing effectiveness (Phase 2)Study completedNCT01246063
What this trial is testing

Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Washington University School of Medicine 40
Early research (Phase 1)Active Not RecruitingNCT06223516
What this trial is testing

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
AbbVie 60
Early research (Phase 1)Active Not RecruitingNCT06325748
What this trial is testing

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Who this might be right for
AML/MDSCD33 Expressing Hematological MalignanciesFLT3 Expressing Hematological Malignancies
Senti Biosciences 21
Testing effectiveness (Phase 2)Study completedNCT00530816
What this trial is testing

Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Amgen 164
Early research (Phase 1)UnknownNCT04677452
What this trial is testing

Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM

Who this might be right for
Safety and Efficacy
The First Affiliated Hospital of Soochow University 24
Early research (Phase 1)Ended earlyNCT02099539
What this trial is testing

QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Altor BioScience 19
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06333509
What this trial is testing

Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL

Who this might be right for
Multiple MyelomaPrimary Plasma Cell Leukemia
CARsgen Therapeutics Co., Ltd. 166
Large-scale testing (Phase 3)Looking for participantsNCT07579234
What this trial is testing

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Shandong New Time Pharmaceutical Co., LTD 261
Early research (Phase 1)Active Not RecruitingNCT04613557
What this trial is testing

Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapse/Refractory Multiple Myeloma
Celyad Oncology SA 18
Testing effectiveness (Phase 2)Looking for participantsNCT06356571
What this trial is testing

Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Plasma Cell Myeloma Refractory
Sanofi 64
Early research (Phase 1)Ended earlyNCT02579824
What this trial is testing

Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Myeloma
M.D. Anderson Cancer Center 14
Early research (Phase 1)Study completedNCT00104923
What this trial is testing

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+1 more
California Cancer Consortium 29
Testing effectiveness (Phase 2)Study completedNCT00027560
What this trial is testing

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+2 more
Memorial Sloan Kettering Cancer Center 51
Testing effectiveness (Phase 2)Study completedNCT03242460
What this trial is testing

The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)

Who this might be right for
Relapsed and/or refractorY Multiple Myeloma
Kosin University Gospel Hospital 55
Testing effectiveness (Phase 2)Study completedNCT05064358
What this trial is testing

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 177
Large-scale testing (Phase 3)Not Yet RecruitingNCT07728188
What this trial is testing

Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
AbbVie 520
Testing effectiveness (Phase 2)Study completedNCT00793572
What this trial is testing

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Who this might be right for
Refractory Plasma Cell Myeloma
Fred Hutchinson Cancer Center 32
Next Page